ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Illumina Inc. (ILMN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong Q4 financial performance, innovative product launch (TruPath Genome), and positive long-term growth potential outweigh the short-term insider selling and mixed analyst ratings. The healthcare sector's defensive nature also makes it attractive in the current market environment.
The MACD is positive and expanding (0.747), indicating bullish momentum. RSI is neutral at 66.765, suggesting no overbought or oversold conditions. The stock is trading above the pivot level (120.038) and near R2 (129.301), showing upward price movement. Moving averages are converging, signaling potential trend continuation.
Strong Q4 financial performance with revenue up 4.98% YoY, net income up 78.61% YoY, and EPS up 84.75% YoY.
Launch of TruPath Genome technology, which enhances genetic disease detection and precision medicine.
Institutional money moving into healthcare as a defensive sector during market volatility.
Positive long-term growth potential with innovative initiatives like NovaSeq X and Billion Cell Atlas.
Insider selling has increased by 287.98% over the last month, which could indicate reduced confidence from insiders.
Mixed analyst ratings with some price target reductions, reflecting cautious sentiment.
Gross margin dropped slightly (-0.68% YoY), which could signal cost pressures.
In Q4 2025, Illumina reported revenue of $1.159 billion (+4.98% YoY), net income of $334 million (+78.61% YoY), and EPS of $2.18 (+84.75% YoY). However, gross margin slightly declined to 65.49% (-0.68% YoY). Overall, the financials show strong growth and profitability improvements.
Analyst ratings are mixed. Piper Sandler and Guggenheim maintain bullish views with price targets of $170, while JPMorgan and UBS are neutral with lower targets of $120 and $135, respectively. Analysts acknowledge strong Q4 results and long-term growth potential but remain cautious about near-term execution risks.
